Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2020 |
| CAGR: | 8.6 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The major factors that drive the European ovarian cancer diagnostics and therapeutics market are increasing geriatric women population, rise in ovarian cancer cases, and greater use of combination therapies for the treatment of ovarian cancer. The incidences of ovarian cancer are high in women, who are aged between 55-64 years. The major symptoms of ovarian cancer include bloating, pelvic and abdominal pain, difficulty in eating, and urinary symptoms. As per Cancer Research UK, ovarian cancer is the fifth most common cancer in Europe for females. Moreover, as per Globocan estimates, Europe recorded 67,771 new ovarian cancer cases in 2018, with 44,576 deaths. With the rising burden of cancer, there is a rising need for effective treatment. Hence, owing to these factors, the market is expected to witness significant growth over the forecast period.
Scope of the Report
As per the scope of the report, Ovarian cancer is caused by uncontrollable cell growth in the ovarian tissue. It is a growing concern and one of the most common causes of death in women.
| By Cancer Type | |
| Epithelial Ovarian Tumors | |
| Ovarian Germ Cell Tumors | |
| Others |
| By Modality | ||||||||
| ||||||||
|
| Geography | ||||||||
|
Key Market Trends
Chemotherapy is Expected to Hold Largest Share of the Europe Ovarian Cancer Diagnostics and Therapeutics Market
Chemotherapy is the most common form of therapeutics used to stop or slow down the growth of cancer cells. Surgery and radiation therapy works by removing, killing, or damaging the cancer cells in a certain area, but chemotherapy works throughout the whole body. This means chemotherapy can kill and damage cancer cells that have spread to other parts of the body, which are far away from the original tumor. Chemotherapy-based drugs have been the choice of treatment over decades and have been the main treatment option for several types of cancer. Hence, owing to the above-mentioned factors, along with the rising burden of ovarian cancer, the market for chemotherapy is expected to grow during the forecast period.
To understand key trends, Download Sample Report
Competitive Landscape
The European ovarian cancer diagnostics and therapeutics market consists of several major players. The companies are implementing certain strategic initiatives, such as mergers and acquisitions, new product launches, and partnerships that help them in strengthening their market position. For instance, in 2019, Bristol-Myers Squibb Company has acquired Celgene, which has widened the company’s pipeline in oncology, hematology, immunology, and cardiovascular disease.
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Burden of Ovarian Cancer
-
4.2.2 Greater Use of Combination Therapies for the Treatment of Ovarian Cancer
-
4.2.3 Rising Geriatric Population
-
-
4.3 Market Restraints
-
4.3.1 Lack of Accurate Diagnosis of Ovarian Cancer
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
-
5.1.1 Epithelial Ovarian Tumors
-
5.1.2 Ovarian Germ Cell Tumors
-
5.1.3 Others
-
-
5.2 By Modality
-
5.2.1 Diagnosis
-
5.2.1.1 Biopsy
-
5.2.1.2 Blood Tests
-
5.2.1.3 Ultrasound
-
5.2.1.4 PET
-
5.2.1.5 CT Scan
-
5.2.1.6 Other Diagnosis
-
-
5.2.2 Therapeutics
-
5.2.2.1 Chemotherapy
-
5.2.2.2 Radiation Therapy
-
5.2.2.3 Immunotherapy
-
5.2.2.4 Hormonal Therapy
-
5.2.2.5 Others
-
-
-
5.3 Geography
-
5.3.1 Europe
-
5.3.1.1 Germany
-
5.3.1.2 United Kingdom
-
5.3.1.3 France
-
5.3.1.4 Italy
-
5.3.1.5 Spain
-
5.3.1.6 Rest of Europe
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Amneal Pharmaceuticals LLC
-
6.1.2 Astrazeneca plc
-
6.1.3 Boehringer Ingelheim International GmbH
-
6.1.4 Bristol Myers Squibb Company
-
6.1.5 Eli Lilly and Company
-
6.1.6 F. Hoffman-La Roche Ltd
-
6.1.7 Glaxosmithkline Plc
-
6.1.8 Johnson and Johnson (Janssen Pharmaceuticals)
-
6.1.9 Pfizer Inc.
-
6.1.10 Siemens Healthineers AG
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Europe Ovarian Cancer Diagnostics and Therapeutics Market market is studied from 2018 - 2026.
What is the growth rate of Europe Ovarian Cancer Diagnostics and Therapeutics Market?
The Europe Ovarian Cancer Diagnostics and Therapeutics Market is growing at a CAGR of 8.6% over the next 5 years.
Who are the key players in Europe Ovarian Cancer Diagnostics and Therapeutics Market?
F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Glaxosmithkline Plc, Johnson and Johnson (Janssen Pharmaceuticals), Eli Lilly and Company are the major companies operating in Europe Ovarian Cancer Diagnostics and Therapeutics Market.
